Valvular & structural heart disease
Heterotopic Crosscaval Transcatheter Tricuspid Valve Replacement for Patients With Tricuspid Regurgitation: The Trillium Device
Authors' conclusion
The Trillium device is a safe and effective device for the treatment of patients with severe or greater TR ineligible for other therapeutic options.
Study context
- Population
- Patients with severe or greater tricuspid regurgitation (TR) ineligible for surgical or other interventional orthotopic tricuspid valve (TV) treatment2,021–2023
- Participants
- 20 patients
- Outcome
- Technical performance, efficacy and safety of heterotopic cross-caval transcatheter TV replacement
- Follow-up
- 30 days
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
- Postprocedural change in central venous pressure (median, Q1-Q3 −5 to −1 mm Hg)
- −3 mm Hg; P = 0.003
- TR severity at the level of the device reduced in all cases
- P < 0.001
Further findings
NYHA functional class · 30 days
- Improvement in NYHA functional class
- P = 0.005
Edema severity score · 30 days
- Trend toward reduction (median change, Q1-Q3 −1 to −0)
- −0.5; P = 0.052
Safety
Adverse events within 30 days
- Death
- 1
- HF hospitalization
- 2
- Hemodialysis
- 2
- Major bleeding
- 2
Original publication
Heterotopic Crosscaval Transcatheter Tricuspid Valve Replacement for Patients With Tricuspid Regurgitation: The Trillium Device. JACC Cardiovasc Interv. Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →